For site information, send an email with site number to
Investigational Site Number 0360003(1.3 mi away)Contact
+11 other location
Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose
of SAR408701 in combination with pembrolizumab in the NSQ NSCLC population
Part 2: To assess the antitumor activity of SAR408701 in combination with pembrolizumab
and pembrolizumab single agent in the NSQ NSCLC population
To assess the safety and tolerability of SAR408701 in combination with pembrolizumab and
pembrolizumab single agent
To assess the durability of the response to treatment with SAR408701 in combination with
pembrolizumab and pembrolizumab single agent
To assess the efficacy on progression-free survival (PFS) of SAR408701 in combination
with pembrolizumab and pembrolizumab single agent
To assess the pharmacokinetics (PK) of SAR408701 and pembrolizumab when given in
combination, and of pembrolizumab when given as a single agent
To assess the immunogenicity of SAR408701 when given in combination with pembrolizumab
The expected duration of the study intervention for participants may vary based on
progression date; median expected duration of study per participant is estimated 11 months
(up to 1 month for screening, a median of 6 months for treatment, and a median of 4 months
for end-of-treatment assessments and safety follow-up visit).
Clinical Study Identifier
Last Modified on
16 November 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.